Vaxxinity Balance Sheet Health

Financial Health criteria checks 3/6

Vaxxinity has a total shareholder equity of $13.4M and total debt of $15.2M, which brings its debt-to-equity ratio to 113.1%. Its total assets and total liabilities are $44.3M and $30.9M respectively.

Key information

113.1%

Debt to equity ratio

US$15.17m

Debt

Interest coverage ration/a
CashUS$30.64m
EquityUS$13.41m
Total liabilitiesUS$30.90m
Total assetsUS$44.31m

Recent financial health updates

Recent updates

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Jan 08
A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Sep 12

Financial Position Analysis

Short Term Liabilities: VAXX's short term assets ($33.2M) exceed its short term liabilities ($17.6M).

Long Term Liabilities: VAXX's short term assets ($33.2M) exceed its long term liabilities ($13.3M).


Debt to Equity History and Analysis

Debt Level: VAXX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if VAXX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if VAXX has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if VAXX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies